文献速递艾滋病与性传播感染

拉替拉韦联合或单用拉米夫定用于HIV-1暴露前预防的药代动力学/药效学研究

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

一项开放标签试验纳入36名HIV阴性女性和男性,随机接受7天拉替拉韦400mg每日两次单药或联合拉米夫定150mg每日两次,交叉洗脱后比较生殖道组织药物浓度及离体HIV-1攻击的保护效果。结果显示联合方案在直肠和阴道组织中提供更高离体保护,且停药后药物浓度持续存在,支持进一步研究该组合用于暴露前预防。

要点

  • 拉替拉韦单药对离体HIV保护有限,联合拉米夫定可增强直肠和阴道组织的保护。
  • 联合方案在直肠组织第2天、阴道组织第8天达到最大离体保护。
  • 停药后拉米夫定在直肠和阴道组织中持久滞留,血浆中清除迅速。

核心结论

  • 拉替拉韦400mg联合拉米夫定150mg显示高水平的离体HIV保护,与停药后阴道和直肠腔室中持续的高药物浓度相关,支持进一步研究这些药物用于暴露前预防。

研究设计与样本

  • 开放标签试验纳入36名HIV阴性女性和男性,随机接受7天拉替拉韦400mg每日两次和7天拉替拉韦400mg+拉米夫定150mg每日两次(洗脱后),或相反顺序。
  • 在基线及使用和停用暴露前预防期间共12天采样血液、唾液、直肠液、直肠组织、阴道液和阴道组织,进行药代动力学和离体HIV-1BaL攻击抗病毒活性检测。
  • 试验注册号NCT03205566。

主要发现

  • 两种药物在第4天达到稳态。
  • 单用拉替拉韦提供适度的离体HIV保护,使用和停用暴露前预防时直肠组织和阴道组织药物水平高于血浆。
  • 停用暴露前预防后,血浆和阴道浓度迅速下降,而直肠中持续存在。
  • 使用暴露前预防时,拉米夫定浓度最高在直肠,其次阴道组织,然后血浆;拉米夫定在血浆中洗脱迅速,而在直肠和阴道中持续存在。
  • 拉替拉韦/拉米夫定相比单用拉替拉韦在使用和停用暴露前预防时均增加离体保护,直肠组织在第2天、阴道组织在第8天达到最大保护。

临床怎么用

  • 联合拉替拉韦和拉米夫定可能增强直肠和阴道组织的HIV暴露前预防保护,尤其停药后组织浓度持续。
  • 需进一步研究以确定该组合用于暴露前预防的剂量和方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1. METHODS: Open-label trial of 36 HIV-negative females and males randomized to 7 days raltegravir 400 mg twice daily and 7 days raltegravir 400 mg+lamivudine 150 mg twice daily (after washout), or vice versa. Blood, saliva, rectal fluid, rectal tissue, vaginal fluid and vaginal tissue were sampled at baseline and on and off PrEP during a total of 12 days, for pharmacokinetics and antiviral activity via ex vivo HIV-1BaL challenge. Ex vivo infectivity was compared with baseline. The trial has been registered in https://clinicaltrials.gov/ with the identifier NCT03205566. RESULTS: Steady state for both drugs was reached by day 4. Dosing with raltegravir alone provided modest ex vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP. Off PrEP, plasma and vaginal concentrations declined rapidly, while persisting in the rectum. On PrEP, the highest lamivudine concentrations were in the rectum, followed by vaginal tissue then plasma. Lamivudine washout was rapid in plasma, while persisting in the rectum and vagina. Raltegravir/lamivudine increased ex vivo protection on and off PrEP compared with raltegravir alone, reaching maximum protection at day 2 in rectal tissue and at day 8 in vaginal tissue. CONCLUSIONS: Raltegravir 400 mg+lamivudine 150 mg showed high levels of ex vivo HIV protection, associated with high drug concentrations persisting after discontinuation in vaginal and rectal compartments, supporting further investigation of these agents for PrEP.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Herrera C, Lwanga J, Lee M, et al. Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). J Antimicrob Chemother. 2021. PMID: 33993302. doi:10.1093/jac/dkab136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。